Cancer Research Institute collaboration with the Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb, and Apexigen will test CD40 antibody APX005M, nivolumab, and chemotherapy in pancreatic cancer patients.
First-of-its kind campaign to fund promising immunotherapy research in Israel, a global leader in cancer research
Fight Colorectal Cancer and the Cancer Research Institute announce the recipient of their jointly-funded $400k grant to support immunotherapy research in metastatic colorectal cancer.
CRI's largest grant to a single investigator will support development of microchip-based research models of cancer and the immune system
The Focused Ultrasound Foundation (FUSF) and the Cancer Research Institute (CRI) are establishing a partnership with the goal of advancing the development of new focused ultrasound (FUS) and cancer immunotherapy treatments.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
AACR19 highlighted incredible advances in our efforts to leverage cutting-edge science in order to improve medical treatment for cancer patients.
Scientists tackled novel immunotherapy strategies that could potentially enable more patients with more types of cancer to benefit.